Brief: Fate Therapeutics Presents New Phase 1 Clinical Data Of Ft819 Off-The-Shelf
09/12/2024 21:27
Dec 9 (Reuters) - Fate Therapeutics Inc FATE.O :
* FATE THERAPEUTICS PRESENTS NEW PHASE 1 CLINICAL DATA OF
FT819
OFF-THE-SHELF, CAR T-CELL PRODUCT CANDIDATE FOR SYSTEMIC LUPUS
ERYTHEMATOSUS
Source text: ID:nGNX9K7zQW
Further company coverage: FATE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Fate Therapeutics
See all newsBrief: Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial Of FT819 For The Treatment Of Lupus Nephritis
Fate Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Fate Therapeutics Q2 loss narrows as expenses fall, revenue rises
Fate Therapeutics Inc expected to post a loss of 27 cents a share - Earnings Preview
Fate Therapeutics Inc expected to post a loss of 27 cents a share - Earnings Preview